Cancer Prevention Pharmaceuticals (CPP) has completed the target enrolment for its phase 3 clinical trial, CPP FAP-310, for assessing CPP-1X/sulindac in adults with familial adenomatous polyposis (FAP).

FAP is a rare genetic disease that commonly develops into colorectal cancer if untreated.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

For the trial, CPP has enrolled 166 patients at 21 research institutes in the US, Canada and Europe.

CPP is currently developing CPP-1X/sulindac as a pharmaco-prevention therapy that is designed to reduce the progression of polyps and tumours related to FAP.

"The completion of target enrolment in this pivotal Phase 3 clinical trial is an important milestone for the non-invasive treatment of FAP."

A randomised, double-blind, phase 3 clinical trial, CPP FAP-310 aims to find out in FAP patients if the combination of CPP-1X and sulindac delays the time to disease progression and subsequent FAP-related events, including the need for surgical and endoscopic procedures.

See Also:

Patients undergoing the clinical trial will receive two years of daily treatments of CPP-1X/sulindac, and time to the first occurrence of any FAP-related event is evaluated during this two-year period.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Cancer Prevention Pharmaceuticals CEO Jeffrey Jacob said: "The completion of target enrolment in this pivotal Phase 3 clinical trial is an important milestone for the non-invasive treatment of FAP, and we look forward to completing the trial and bringing to market a first-in-class pharmaco-prevention therapeutic.

"For this clinical trial, we have worked closely with many groups, including the US Food and Drug Administration and the European Medicines Agency to develop clinically relevant trial endpoints, with top clinical researchers and medical centres in the design and implementation of the trial, and with patient advocacy organisations to support awareness of the trial in the FAP community."

The company said that patients with typical presentation of FAP experience a genetic mutation that conveys an extremely high-risk of developing colon cancer, and they start to develop multiple benign polyps in the colon in their early teens.

Ultimately, the colon becomes carpeted with hundreds to thousands of polyps, with some becoming become cancerous if not treated.

For most FAP patients, existing medical practice suggests the surgical removal of the colon and sometimes the rectum followed by a lifetime of monitoring of the upper GI, retained rectum or ileal pouch, additional operations and a reduced quality of life.